Coroflex® ISAR NEO PMCF Study

Prior treatment

• Patients with known sensitivity to Sirolimus, the carrier Probucol, the procedural co-medication or the alloying component of the stent

Other illness

• Patients with acute coronary syndrome (ACS) in a situation of cardiogenic shock (Killip 4).
• Patients with contraindications or hypersensitivity to sirolimus

Lab values

• Patients in whom anti-platelet and/or anti-coagulation therapy is contraindicated

Other

• Patients with express refusal by the patient to participate in the study.
• Patients pregnant women and lactating women.
• Patients with lesions, that possibly can not be treated successfully with Percutaneous transluminal Coronary Angioplasty (PTCA) or stent implantation
• Patients with known sensitivity to contrast agents who cannot be premedicated.
• Patients with a life expectancy of less than 2 years
• Patients included in other clinical trials

• Coroflex® ISAR NEO is intended to be used for
• Patients must be at least 18 years of age AND
• The patient must fulfill the standard recommendations for Percutaneous Coronary Intervention (PCI) based on the last European Society of Cardiology (ESC) recommendations within his/ her regular treatment or that the use of the product has already been decided within the regular planning of the patient's treatment AND
• Patients with Novo lesion length 2-4 mm AND
• Informed consent signed